Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall
Posted by
www.biotecnika.org
"We understand from Mylan NV's press release dated January 8, 2020,
that Mylan Pharmaceuticals has initiated a voluntary recall of three
lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to
detected trace amounts of impurity...," Solara Active Pharma Sciences
in a filing to BSE.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/solara-active-pharma-to-conduct-internal-probe-on-nizatidine-api-amid-mylan-recall/articleshow/73167327.cms
Subscribe to:
Post Comments (Atom)
Post a Comment